Sales of GlaxoSmithKline (GSK) diabetes drug Avandia have taken a pounding since a study showed that the drug increased heart risk. According to a research note from Morgan Stanley, Avandia and a related drug Avandamet had a combined 35.3 percent share of the market for pharmaceuticals in their class in the week ended June 1. Before the study about the risks of the drug appeared in The New England Journal of Medicine, that share was 53.8%.
News reports have indicated that GSK has tried to discredit the journal report and may have tried to intimidate a doctor who offered similar findings to the FDA. The agency is now considering putting a warning on the medication.
Looks like the strong-arming didn’t work.
Douglas A. McIntyre
Smart Investors Are Quietly Loading Up on These “Dividend Legends”
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats.
There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside.
If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
By providing your email address, you agree to receive communications from us regarding website updates and other offerings that may be of interest to you.
You have the option to opt-out of these emails at any moment. For more information, please review our Disclaimer and Terms of Use.
